ALKERMES | ALKS - PE Price to Earnings


ALKERMES reported 262.4 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
AbbVie 23.45 0.51 Sep/2026
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
ALKERMES 262.4 126.59 Sep/2026
Amgen 18.6 0.53 Sep/2026
Biogen 29.15 5.92 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Eli Lilly 64.5 31.61 Sep/2026
Gilead Sciences 17.68 4.18 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
J&J 25.86 3.57 Sep/2026
Malin Corporation 11.81 0.72 Jun/2023
Merck 34.36 2.11 Sep/2026
Neurocrine Biosciences 83.17 61.07 Sep/2026
Otsuka Holdings 15.2 2.2 Sep/2026
Ovoca Bio 1.83 3.29 Jun/2024
Pfizer 15.2 3.72 Sep/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Vertex Pharmaceuticals 29.35 1.3 Sep/2026